ALXO - alxoncology.com Price to Earnings Adjusted for Growth Rate

Corporate company logo of ALX Oncology (ALXO)

The PEG ratio chart allows for an assessment of the potential of ALX Oncology Holdings (ALXO), considering the colossal pricing power resulting from inelastic demand for the unique evorpacept. The business focuses on the selective blocking of CD47 to protect erythrocytes, while a patent moat provides an advantage in combination therapy. The current 0.00 indicator determines the magnitude of the metric, helping to understand how fairly the market prices in the development rates of this innovative project.

ALXO: ALX Oncology PEG Multiple 07/04/2022 - 11/18/2026

Metric breakdowns and analytics for alxoncology.com (ALXO)

- market value and analyst target forecast:
Summary company analytics:ALXO ALX Oncology Holdings Inc.
Original product of ALX Oncology Holdings

ALX Oncology Holdings (ALXO) focus on CD47 blockade creates significant risks due to low drug portfolio diversification. When analyzing the PEG ratio, an investor compares the current P/E multiple with the earnings growth rate. The value of 0.00 reflects the degree of asset overvaluation relative to its expansion. A metric below one signals that the company is undervalued. This allows for an objective assessment of business resilience amid fierce competition within the oncology sector.

Competitors of ALX Oncology Holdings

ImmunityBio, Inc. (IBRX) - Price to Net Income Growth Ratio|Immunocore Holdings - Price/Earnings to Growth Multiple|Janux Therapeutics, Inc. (JANX) - Price to Earnings Adjusted for Growth Rate|RCUS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ZYME (Zymeworks)|TNGX: PEG Multiple|IOVA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio immatics.com|Price/Earnings to Growth Multiple xencor.com (XNCR)|Price/Earnings to Growth Ratio Compass Therapeutics Inc (CMPX)|Price/Earnings to Growth Multiple Replimune Corp REPL|Lyell - Price/Earnings to Growth Multiple|PEG Multiple Innate Pharma S.A IPHA|PYXS - Price/Earnings to Growth Ratio|CGEN (Compugen) - Growth-Adjusted P/E Ratio|IO Biotech Inc. (IOBT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Sutro Bio (STRO)|Price/Earnings to Growth Multiple INKT|HOWL - Price to Net Income Growth Ratio|Price/Earnings to Growth Multiple IMMX (Immix Biopharma, Inc.)|CUE (Cue Biopharma) - Growth-Adjusted Payback Ratio|PEG Multiple PDSB (PDS Biotechnology)|Growth-Adjusted Payback Ratio SONN|MAIABiotech.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Liminatus|Lava Tx (LVTX) - Price/Earnings to Growth Ratio|NextCure, Inc. - Growth-Adjusted Payback Ratio|LPTX (Leap Tx) - PEG Multiple|PEG Multiple intensitytherapeutics.com|Price/Earnings to Growth Ratio senseibio.com (SNSE)|TOVX: Market Cap to Earnings and Growth Ratio|Gritstone bio - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income kinetabio.com (KA)|NEXI - Price/Earnings to Growth Ratio|Turnstone Biologics Corp - Company Value to Earnings Growth Ratio|VCNX: PEG Multiple|Harpoon Therapeutics Corp (HARP) - PEG Multiple